DDInter222 DDInter1956
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) resembles {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) upregulates {v} (Gene) ZW10
ZW10 {u} (Gene) is downregulated by {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) causes {v} (Side Effect) Pollakiuria
Pollakiuria {u} (Side Effect) is caused by {v} (Compound) Zalcitabine
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Gemcitabine
Gemcitabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is upregulated by {v} (Compound) Gemcitabine
Gemcitabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Bortezomib {u} (Compound) upregulates {v} (Gene) ZW10
ZW10 {u} (Gene) is regulated by {v} (Gene) ANO10
ANO10 {u} (Gene) is upregulated by {v} (Compound) Zalcitabine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) resembles Zalcitabine (Compound)
Bortezomib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Zalcitabine (Compound)
Bortezomib (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Zalcitabine (Compound)
Bortezomib (Compound) upregulates ZW10 (Gene) and ZW10 (Gene) is downregulated by Zalcitabine (Compound)
Bortezomib (Compound) causes Pollakiuria (Side Effect) and Pollakiuria (Side Effect) is caused by Zalcitabine (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Zalcitabine (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cytarabine (Compound) and Cytarabine (Compound) resembles Zalcitabine (Compound)
Bortezomib (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Gemcitabine (Compound) and Gemcitabine (Compound) resembles Zalcitabine (Compound)
Bortezomib (Compound) downregulates PCNA (Gene) and PCNA (Gene) is upregulated by Gemcitabine (Compound) and Gemcitabine (Compound) resembles Zalcitabine (Compound)
Bortezomib (Compound) upregulates ZW10 (Gene) and ZW10 (Gene) is regulated by ANO10 (Gene) and ANO10 (Gene) is upregulated by Zalcitabine (Compound)